Enfuvirtide: The first fusion inhibitor for the treatment of patients with HIV-1 infection

Formulary

Volumn 38, Issue 4, 2003, Pages 204-222

  Coleman, Craig I ^a   Musial, Bogdan L ^b   Ross, Jack ^c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NEW BRITAIN GENERAL HOSPITAL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; FORTAVSE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TRI 001; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DRUG COST; DRUG FEVER; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION PAIN; INSOMNIA; NAUSEA; PHENOTYPE; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

EID: 0141924763     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. CDC HIV/AIDS Surveillance Report. Available at: www.cdc.gov/hiv/stats. htm (accessed 11/12/2002).
2. Panel on Clinical Practices for Treatment of HIV Infection, convened by Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (February 4, 2002). Available at: www.hiv atis.org (accessed 11/12/2002).
3. Vittinghoff E, Scheer S, O'Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999;179:717-20.
4. Fuzeon [enfuvirtide) package insert. Nutley, NJ and Durham, NC: Roche Laboratories Inc, and Trimeris, Inc; March 2003.
5. Sweetman S (Ed), Martindale: The Complete Drug Reference. London: Pharmaceutical Press. Electronic version, Micromedex, Greenwood Village, Colo; Edition expired December 2002.
6. D'Souza MP, Cairns JS, Plaeger SF. Current evidence and future directions for targeting HIV entry. JAMA 2000;84:215-22.
7. Kilby MJ, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Medicine 1998;11:1302-7.
8. Barney S, Guthrie K, Davis D, et al. Pentafuside (T-20), a novel inhibitor of HIV-1 fusion and infection, is synergistic when used in combination with reverse transcriptase (RT) and protease inhibitors (PI) in vitro. Antiviral Res 1998;37:A54.
9. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type-1 resistance to gp41-derived inhibitory peptides. J Virol 1998;72:986-93.
10. Greenberg M, McDanal C, Stanfield-Oakley S, et al. Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage. Presented at: 8th Conference on Retroviruses and opportunistic Infections (CROI), Chicago, Ill, February 4-8, 2001; Abstract 473.
11. Sista P, Melby T, Greenberg ML, et al. Characterization of baseline and treatment-emergent resistance to T-20 (enfuvirtide) observed in Phase II clinical trials: substitution in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates. Antiviral Ther 2002;7:S23.
12. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Chemother 2002;46:1896-1905.
13. Kilby MJ, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in infected adults. AIDS Research and Human Retroviruses 2002;18:685-93.
14. Mink MA, Janumpalli S, Davison DK, et al. Correlation of gp41 binding and antiviral potencies of the fusion inhibitor T-20 using clinical trial isolate-derived sequences. Presented at: 8th Conference on retroviruses and Opportunistic Infections (CROI), Chicago, Ill, February 4-8, 2001; Abstract 474.
15. Lu J, Sista P, Cammack N, et al. Fitness of HIV-1 clinical isolates resistant to T-20 (enfuvirtide). Antiviral Ther 2002;7:S56.
16. Zollner B, Feucht HH, Schroter M, et al. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS 2001;15:935-6.
17. Xu L, Hue S, Taylor S, et al. Minimal variation in T-20 binding domain of different HIV subtypes from antiretroviral naïve and experienced patients. AIDS 2002;16:1684-6.
18. Derdeyn C, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with coreceptors. J Virol 2001;75:8605-14.
19. Zhang X, Nieforth K, Lang JM, et al. Pharmacokinetics of the plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartmental disposition. Clin Pharmacol Ther 2002;72:10-19.
20. Kosel B, et al, for the PACTG 1005 Study Team. Pharmacokinetics of selected doses of T-20, a fusion inhibitor, in HIV-1 infected children. Presented at: 8th Conference on Retroviruses and Opportunistic Infections (CROI), Chicago, Ill, February 4-8, 2001; Abstract 726.
21. Bellibas SE, Pepper T, Dorr A, et al. Pharmacokinetics and safety of 2 mg/kg T-20 in combination therapy in HIV infected children and adolescents. Presented at: XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002; Poster TuPeB4632.
22. Patel IH, Lalezari J, Dorr A, et al. Enfuvirtide (T-20) is optimally absorbed from three different subcutaneous injection sites. Presented at: XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002; Poster TuPeB4542.
23. Lalezari J, Eron J, Carlson M, et al. Safety, pharmacokinetics and antiviral activity of T-20 as a single agent in heavily pre-treated patients. Presented at: 6th Conference on Retroviruses and Opportunistic Infections (CROI), Chicago, Ill, January 31-February 4, 1999; Abstract CB13.
24. Lalezari J, DeJesus E, Northfelt D, et al. A week 48 assessment of a randomized, controlled, open-labeled phase II trial (T20-206) Evaluating three doses of T-20 in PI-Experienced, NNRTI-naïve patients infected with HIV-1. Presented at: 9th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Wash, February 24-28, 2002; Abstract 418-W.
25. Wheat LJ, Lalezari J, Kilby M, et al. 48 week assessment of high strength T-20 in multi-class experienced patients. Presented at: 9th Conference on Retroviruses and Opportunistic Infections; Seattle, Wash, February 2002; Poster 417-W.
26. Clotet B, Lazzarin A, Cooper D, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in Europe and Australia (TORO2). Presented at: XIV International AIDS Conference; Barcelona, Spain, July 7-12, 2002; Poster LbOr19A.
27. Henry K, Lalezari J, O'Hearn M, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in North America and Brazil. Presented at: XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002; Poster LbOr19B.
28. Church JA, Cunningham C, Hughes M, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infec Dis J 2002;21:653-9.
29. Food and Drug Administration. Guidance for industry: Clinical considerations for accelerated and traditional approval of antiretroviral drugs using plasma HIV RNA measurements [draft guidance]. August 1999. Available at: www.fda.gov/cder/guidance/index.htm.
30. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone: Week 24 response among categories of treatment experience and baseline (BL) HIV antiretroviral (ARV) resistance. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, Calif, September 27-30, 2002; Abstract H-1074.
31. Lange J, Lazzarin A, Cloetet B, et al, on behalf of the TORO 2 Study Group. Enfuvirtide (T-20) in combination with optimized background (OB) regimen vs. OB alone: Week 24 response among categories of baseline (BL) demographics, treatment experience and HIV antiretroviral (ARV) resistance. Presented at: 6th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, November 17-21, 2002; Poster PL14.3.
32. Drobnes C, Fang L, Nelson E, et al. Tolerability of enfuvirtide (T-20) during chronic therapy in Phase II trials. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, Calif, September 27-30, 2002; Abstract H-171.
33. Delfraissy JF, Montaner J, Eron J, et al, for the TORO study team. Summary of pooled efficacy and safety analyses of enfuvirtide (ENF) treatment for 24 weeks in TORO 1 and TORO 2 phase III trials in highly antiretroviral (ARV) treatment-experienced patients. Presented at: 10th Conference on Retroviruses and Opportunistic Infections, Boston, Mass, February 2002; Poster 568.
34. Cohen CJ, Dusek A, Green J, et al. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care and STDs 2002;16:327-35.
35. Green J, Salgo MP, Delehanty J. Patient survey on injection of enfuvirtide (T-20): ease of use and impact on activities. Presented at: XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002; Poster TuPeB4480.
36. Boyd M, Ruxrungtham K, Zhang X, et al. Enfuvirtide-investigations on the drug interaction potential in HIV-infected patients. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; Boston, Mass, February 2002; Poster 541.
37. Nagashima KA, Thompson JA, Rosenfield SI, et al. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001;183:1121-5.
38. Tremblay CL, Kollmann C, Giguel F, et al. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. J Acquir Immune Defic Syndr 2000;25:99-102.
39. Record high price set for new Roche AIDS drug. [Press release]. Reuters; February 24, 2003. Accessed at: www.medscape.com/viewarticle/449798.